Lanzhou, China – 18 Sep 2026 – The Gansu Public Resources Trading Center publicized the formal review results of the ninth batch of new drug sunshine listing applications for 2026, disclosing that of 595 products submitted through the national joint review mechanism (联审通办) and the provincial bidding‑and‑procurement management subsystem as of 10 September 2026, only 229 qualified for platform listing while 366 failed the screening. The publicity period runs 20–22 September 2026, with online appeals due by 24:00 on 22 September 2026.
Policy Snapshot
| Item | Detail |
|---|---|
| Agency | Gansu Public Resources Trading Center; supervised by the Gansu Provincial Healthcare Security Bureau |
| Document | Publicity of Formal Review Results – Ninth Batch of New Drug Sunshine Listings, 2026 |
| Legal Basis | Gansu Service Guide for the Drug & Medical Consumables Procurement Management Subsystem (v1.0); Gansu Drug Listing/Delisting Rules |
| Applications Received | 595 (national joint review + provincial subsystem, as of 10 Sep 2026) |
| Passed Formal Review | 229 (≈ 38.5 % pass rate) |
| Failed Formal Review | 366 – itemized in the annexed publicity table (.xls) |
| Publicity Period | 20–22 Sep 2026 |
| Appeal Deadline | 24:00, 22 Sep 2026, online only |
| Contacts | Business: 0931‑2909290 / 2909266 / 2909265; Supervision: 0931‑8127609 (Provincial Healthcare Security Bureau) |
Review Results & Compliance Requirements
- Formal Review Outcomes: The 229 qualifying products will proceed to sunshine listing on the provincial platform, subject to completion of the publicity period; the 366 rejected products are listed in the annexed Formal Review Results Publicity Table, giving affected manufacturers a clear, product‑level basis for appeal.
- Price Declaration Undertakings: Listing prices are self‑declared by enterprises under the good‑faith principle and must not exceed Gansu’s provincial price‑management requirements – placing documentation and pricing integrity squarely on applicants.
- Cross‑Province Price‑Linkage Rule: If a listed drug’s price is reduced in any other province, the manufacturer must proactively apply for a matching price cut in Gansu within one month – failure to do so triggers suspension of trading qualification, extending the nationwide price‑linkage discipline into Gansu’s procurement channel.
- Appeals Strictly Online: Objections must be filed via the “Appeal & Query” module under the “New Drug Listing Application” menu of the Gansu National Healthcare Insurance Information Platform procurement subsystem; paper and email submissions are not accepted, and non‑conforming filings will be rejected with any resulting losses borne by the enterprise.
Market Impact & Outlook
- Selective Gatekeeping: A ≈ 38.5 % pass rate (229 of 595) signals rigorous formal screening in Gansu, reinforcing that completeness and accuracy of submission dossiers – not price alone – determine platform access.
- National‑Provincial Convergence: The batch combined applications from the national joint review mechanism with the provincial subsystem, reflecting China’s ongoing integration of drug procurement access points across provinces.
- Pricing Discipline Tightening: The one‑month cross‑province price‑adjustment obligation, backed by trading suspension, aligns Gansu with the hardening nationwide enforcement of external‑reference pricing for listed drugs.
- Immediate Action Window: With the publicity period and appeal deadline both closing on 22 September 2026, manufacturers among the 366 rejected products face a same‑week turnaround to challenge results or prepare compliant resubmissions in future batches.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding appeal outcomes, listing approvals, price‑adjustment obligations, and trading‑qualification status for drug products in Gansu Province. Actual results may differ due to risks including appeal handling decisions, enterprise remediation progress, and subsequent policy adjustments by the Gansu Public Resources Trading Center and the Provincial Healthcare Security Bureau.-China Health Reform Pulse
Policy Source: https://sjfz.ggzyjy.gansu.gov.cn:19002/#/details-medicine?params=H4sIAAAAAAAAA6tWykxRslIyNLewNDcyNTSyMDc0VaoFAElMeS4WAAAA&pop=true